EXCEDRIN (MIGRAINE RELIEF) Drug Patent Profile
✉ Email this page to a colleague
When do Excedrin (migraine Relief) patents expire, and when can generic versions of Excedrin (migraine Relief) launch?
Excedrin (migraine Relief) is a drug marketed by Haleon Us Holdings and is included in one NDA.
The generic ingredient in EXCEDRIN (MIGRAINE RELIEF) is acetaminophen; aspirin; caffeine. There are sixty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the acetaminophen; aspirin; caffeine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EXCEDRIN (MIGRAINE RELIEF)?
- What are the global sales for EXCEDRIN (MIGRAINE RELIEF)?
- What is Average Wholesale Price for EXCEDRIN (MIGRAINE RELIEF)?
Summary for EXCEDRIN (MIGRAINE RELIEF)
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Clinical Trials: | 1 |
| DailyMed Link: | EXCEDRIN (MIGRAINE RELIEF) at DailyMed |
-patent-expirations.png "EXCEDRIN (MIGRAINE RELIEF) drug patent expirations")
US Patents and Regulatory Information for EXCEDRIN (MIGRAINE RELIEF)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Haleon Us Holdings | EXCEDRIN (MIGRAINE RELIEF) | acetaminophen; aspirin; caffeine | TABLET;ORAL | 020802-001 | Jan 14, 1998 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EXCEDRIN (MIGRAINE RELIEF)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Haleon Us Holdings | EXCEDRIN (MIGRAINE RELIEF) | acetaminophen; aspirin; caffeine | TABLET;ORAL | 020802-001 | Jan 14, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Haleon Us Holdings | EXCEDRIN (MIGRAINE RELIEF) | acetaminophen; aspirin; caffeine | TABLET;ORAL | 020802-001 | Jan 14, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EXCEDRIN (MIGRAINE RELIEF)
See the table below for patents covering EXCEDRIN (MIGRAINE RELIEF) around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
